Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden

IMPORTANCE: The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintanilha, Julia C. F., Graf, Ryon P., Fisher, Virginia A., Oxnard, Geoffrey R., Ellis, Haley, Panarelli, Nicole, Lin, Douglas I., Li, Gerald, Huang, Richard S. P., Ross, Jeffrey S., Myer, Parvathi A., Klempner, Samuel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871803/
https://www.ncbi.nlm.nih.gov/pubmed/36689222
http://dx.doi.org/10.1001/jamanetworkopen.2022.52244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871803/
https://www.ncbi.nlm.nih.gov/pubmed/36689222
http://dx.doi.org/10.1001/jamanetworkopen.2022.52244

Ejemplares similares